Category: Press Release

AVS Enrolls First Patient in U.S. Pivotal Intravascular Lithotripsy Study

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has enrolled the first patient(s) in its U.S. pivotal trial for Pulsatile Intravascular Lithotripsy (PIVL) therapy. 

AVS Partners with the Jacobs Institute to Expedite Clinical Trials for Coronary and Carotid Indications

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy platform, today announced it has entered into a strategic agreement with the Jacobs Institute, a nonprofit medical device innovation center in Buffalo, N.Y., led by Adnan Siddiqui, M.D. 

AVS Receives IDE Approval from FDA for Pivotal Intravascular Lithotripsy Study

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial for pulsatile intravascular lithotripsy (PIVL) therapy. The POWER-PAD-II clinical study will evaluate… Read more »

AVS Appoints Elizabeth Galle as Vice President of Clinical Affairs

BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced the appointment of Elizabeth Galle as the company’s new Vice President of Clinical Affairs. 

AVS’s Pulsatile Intravascular Lithotripsy Technology Attracts an Additional $8.8M to Close $28.8M Series B Round

BOSTON–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it closed an additional $8.8 million in new financing, bringing its Series B round to $28.8 million total. The funding will continue to support clinical trials for the company’s device for… Read more »

AVS Raises $20 Million in Series B Round to Advance Pulsatile Intravascular Lithotripsy (PIVL) Solutions

BOSTON–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it raised $20 million in Series B financing. The new funding will accelerate clinical trial timelines for the company’s device for peripheral application in pulsatile intravascular lithotripsy (PIVL) cases and advance… Read more »

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Pulsatile Intravascular Lithotripsy shows promise as new treatment therapy for severely calcified vessels ANN ARBOR, Mich. – September 15, 2022, — AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, today announced enrollment, successful treatment, and positive 30-day follow up data of the first… Read more »